Market Overview

Jon Najarian Highlights Unusual Options Activity In Biogen

Jon Najarian Highlights Unusual Options Activity In Biogen

Biogen Inc (NASDAQ: BIIB) traded sharply higher on Tuesday on better than expected earnings and positive news about its Alzheimer's drug. The company surprised investors by revealing that it will seek the regulatory approval of its Alzheimer's treatment.

Jon Najarian noticed some unusual options activity in the name after the sharp move higher. He said on CNBC's "Fast Money Halftime Report" that options traders were selling the October $300 calls in Biogen. Around 5,000 contracts were sold in the first half of the session on Tuesday as traders were betting that the stock won't continue to move higher, above $300.

Related Links:

Biogen Plans Filing For Failed Alzheimer's Drug After New Analysis Option Traders Hit The Jackpot On UPS News

Posted-In: CNBC Fast Money Halftime Report Jon NajarianOptions Markets Media


Related Articles (BIIB)

View Comments and Join the Discussion!
Lightning Fast
Market News Service
$199 Free 14 Day Trial
Book A Demo
Learn How You Can Succeed In The Market With Benzinga Pro

Fastest Market News

Real-Time News Alerts

Customizable News Filters

Book A Demo

PreMarket Prep: A Biotech Surprise, Stamps Shorts Take A Licking, Debating McDonald's Earnings Move

Cresco Labs CEO: The Future Of Cannabis Legalization Includes Social Equity